TSX closed
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Get 200 free trades when you open an eligible CIBC Investor's Edge account.

  • 200 free stock & ETF trades
  • Unlimited commission-free trades on 180+ select ETFs
  • Offer ends September 30, 2026
Stocks/TSX/MRK

Merck CDR (CAD Hedged) (MRK : TSX)

Common Stock

$33.42

CAD

-0.68 (-1.99%)

Last updated: 2026-08-27

Get MRK alerts:

MRK

Merck CDR (CAD Hedged)

Source:WealthAwesomeWealthAwesome
$4.89 (17.14%)
30 day period
$28.18$31.52$34.86Jul 16Aug 7Aug 27

Performance

1 Day

-1.99%

1 Week

+0.78%

1 Month

+13.56%

YTD

+39.13%

Key Statistics

Market Cap

$296.29B

52W High

$34.90

52W Low

$17.26

P/E Ratio

121.79

50 Day MA

$29.03

200 Day MA

$27.03

Beta

-

Dividend Yield

9.52%

Advertisement

Technical Indicators

Price vs 50-Day SMA

Above 50 SMA

Price vs 200-Day SMA

Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
8/27/2026$33.54$33.81$33.30$33.42$33.423,531
8/26/2026$34.59$34.59$34.00$34.10$34.106,823
8/25/2026$34.03$34.90$34.00$34.86$34.8613,809
8/24/2026$33.85$33.85$33.30$33.66$33.666,556
8/21/2026$33.30$34.36$33.30$34.05$34.0512,633
8/20/2026$33.64$33.95$33.16$33.16$33.1627,285
8/19/2026$32.59$34.15$32.37$33.95$33.9543,719
8/18/2026$30.65$30.65$30.15$30.18$30.185,519
8/17/2026$30.30$30.33$30.29$30.33$30.33361
8/14/2026$29.94$30.24$29.90$30.24$30.2420,857

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on MRK's historical volatility

HistoricalForecast68%95%
C$23.64C$32.40C$41.17C$49.94C$58.71C$67.47TodayApr 21Jun 24Aug 27Oct 9Nov 22Jan 4

30-Day Vol

41.4%

Annualized

90-Day Vol

34.8%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$39.95

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$35.47C$30.75C$40.91
60 trading daysC$37.65C$30.76C$46.06
90 trading daysC$39.95C$31.20C$51.16

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Merck CDR (CAD Hedged)

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Financials

Revenue (TTM)
$0
EBITDA
-
Profit Margin
0.00%
ROE (TTM)
3690.70%
EPS (Diluted)
0.00
Book Value
-

Recent Dividends

$0.000$0.096$0.1922025-03-17: $0.18372025-06-16: $0.18512025-09-15: $0.18482025-12-15: $0.1915Mar 25Sep 25Dec 25

$0.1915CAD

Ex: Dec 15, 2025

$0.1848CAD

Ex: Sep 15, 2025

$0.1851CAD

Ex: Jun 16, 2025

$0.1837CAD

Ex: Mar 17, 2025

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About MRK

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
PDIPredictive Discovery Limited$4.10+336.17%
ELREastern Platinum Limited$0.48+37.14%
GRCGold Springs Resource Corp$0.07+15.38%
CJR-BCorus Entertainment Inc$0.04+14.29%
EGLXEnthusiast Gaming Holdings Inc$0.04+12.50%
CVVYCavvy Energy Ltd.$2.18+12.37%
RTGRTG Mining Inc$0.05+11.11%
BBBlackBerry Ltd$11.97+10.83%

Advertisement